Browse CMPK2

Summary
SymbolCMPK2
Namecytidine monophosphate (UMP-CMP) kinase 2, mitochondrial
Aliases TYKi; UMP-CMPK2; cytidylate kinase 2; TMPK2; mitochondrial UMP-CMP kinase; thymidine monophosphate kinase 2; ......
Chromosomal Location2p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion
Domain -
Function

May participate in dUTP and dCTP synthesis in mitochondria. Is able to phosphorylate dUMP, dCMP, CMP, UMP and monophosphates of the pyrimidine nucleoside analogs ddC, dFdC, araC, BVDU and FdUrd with ATP as phosphate donor. Efficacy is highest for dUMP followed by dCMP; CMP and UMP are poor substrates. May be involved in mtDNA depletion caused by long term treatment with ddC or other pyrimidine analogs. Also displays broad nucleoside diphosphate kinase activity.

> Gene Ontology
 
Biological Process GO:0002237 response to molecule of bacterial origin
GO:0006165 nucleoside diphosphate phosphorylation
GO:0006220 pyrimidine nucleotide metabolic process
GO:0006221 pyrimidine nucleotide biosynthetic process
GO:0006227 dUDP biosynthetic process
GO:0006233 dTDP biosynthetic process
GO:0006235 dTTP biosynthetic process
GO:0009132 nucleoside diphosphate metabolic process
GO:0009133 nucleoside diphosphate biosynthetic process
GO:0009138 pyrimidine nucleoside diphosphate metabolic process
GO:0009139 pyrimidine nucleoside diphosphate biosynthetic process
GO:0009141 nucleoside triphosphate metabolic process
GO:0009142 nucleoside triphosphate biosynthetic process
GO:0009147 pyrimidine nucleoside triphosphate metabolic process
GO:0009148 pyrimidine nucleoside triphosphate biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009186 deoxyribonucleoside diphosphate metabolic process
GO:0009189 deoxyribonucleoside diphosphate biosynthetic process
GO:0009196 pyrimidine deoxyribonucleoside diphosphate metabolic process
GO:0009197 pyrimidine deoxyribonucleoside diphosphate biosynthetic process
GO:0009200 deoxyribonucleoside triphosphate metabolic process
GO:0009202 deoxyribonucleoside triphosphate biosynthetic process
GO:0009211 pyrimidine deoxyribonucleoside triphosphate metabolic process
GO:0009212 pyrimidine deoxyribonucleoside triphosphate biosynthetic process
GO:0009219 pyrimidine deoxyribonucleotide metabolic process
GO:0009221 pyrimidine deoxyribonucleotide biosynthetic process
GO:0009262 deoxyribonucleotide metabolic process
GO:0009263 deoxyribonucleotide biosynthetic process
GO:0009265 2'-deoxyribonucleotide biosynthetic process
GO:0009394 2'-deoxyribonucleotide metabolic process
GO:0019692 deoxyribose phosphate metabolic process
GO:0032496 response to lipopolysaccharide
GO:0046072 dTDP metabolic process
GO:0046075 dTTP metabolic process
GO:0046077 dUDP metabolic process
GO:0046385 deoxyribose phosphate biosynthetic process
GO:0046939 nucleotide phosphorylation
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071396 cellular response to lipid
GO:0072527 pyrimidine-containing compound metabolic process
GO:0072528 pyrimidine-containing compound biosynthetic process
GO:1901293 nucleoside phosphate biosynthetic process
Molecular Function GO:0004127 cytidylate kinase activity
GO:0004550 nucleoside diphosphate kinase activity
GO:0004798 thymidylate kinase activity
GO:0009041 uridylate kinase activity
GO:0016776 phosphotransferase activity, phosphate group as acceptor
GO:0019201 nucleotide kinase activity
GO:0019205 nucleobase-containing compound kinase activity
GO:0033862 UMP kinase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00240 Pyrimidine metabolism
hsa01100 Metabolic pathways
Reactome -
Summary
SymbolCMPK2
Namecytidine monophosphate (UMP-CMP) kinase 2, mitochondrial
Aliases TYKi; UMP-CMPK2; cytidylate kinase 2; TMPK2; mitochondrial UMP-CMP kinase; thymidine monophosphate kinase 2; ......
Chromosomal Location2p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CMPK2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCMPK2
Namecytidine monophosphate (UMP-CMP) kinase 2, mitochondrial
Aliases TYKi; UMP-CMPK2; cytidylate kinase 2; TMPK2; mitochondrial UMP-CMP kinase; thymidine monophosphate kinase 2; ......
Chromosomal Location2p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CMPK2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCMPK2
Namecytidine monophosphate (UMP-CMP) kinase 2, mitochondrial
Aliases TYKi; UMP-CMPK2; cytidylate kinase 2; TMPK2; mitochondrial UMP-CMP kinase; thymidine monophosphate kinase 2; ......
Chromosomal Location2p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CMPK2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.40.4
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2830.812
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.8980.326
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.7480.0434
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.9390.538
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5130.804
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0520.918
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3120.776
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.330.8
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.840.11
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.5270.406
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.330.0368
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CMPK2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCMPK2
Namecytidine monophosphate (UMP-CMP) kinase 2, mitochondrial
Aliases TYKi; UMP-CMPK2; cytidylate kinase 2; TMPK2; mitochondrial UMP-CMP kinase; thymidine monophosphate kinase 2; ......
Chromosomal Location2p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CMPK2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCMPK2
Namecytidine monophosphate (UMP-CMP) kinase 2, mitochondrial
Aliases TYKi; UMP-CMPK2; cytidylate kinase 2; TMPK2; mitochondrial UMP-CMP kinase; thymidine monophosphate kinase 2; ......
Chromosomal Location2p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CMPK2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CMPK2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCMPK2
Namecytidine monophosphate (UMP-CMP) kinase 2, mitochondrial
Aliases TYKi; UMP-CMPK2; cytidylate kinase 2; TMPK2; mitochondrial UMP-CMP kinase; thymidine monophosphate kinase 2; ......
Chromosomal Location2p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CMPK2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCMPK2
Namecytidine monophosphate (UMP-CMP) kinase 2, mitochondrial
Aliases TYKi; UMP-CMPK2; cytidylate kinase 2; TMPK2; mitochondrial UMP-CMP kinase; thymidine monophosphate kinase 2; ......
Chromosomal Location2p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CMPK2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCMPK2
Namecytidine monophosphate (UMP-CMP) kinase 2, mitochondrial
Aliases TYKi; UMP-CMPK2; cytidylate kinase 2; TMPK2; mitochondrial UMP-CMP kinase; thymidine monophosphate kinase 2; ......
Chromosomal Location2p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CMPK2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCMPK2
Namecytidine monophosphate (UMP-CMP) kinase 2, mitochondrial
Aliases TYKi; UMP-CMPK2; cytidylate kinase 2; TMPK2; mitochondrial UMP-CMP kinase; thymidine monophosphate kinase 2; ......
Chromosomal Location2p25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CMPK2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.